Asiapharm Group's net profit after tax grew 2.8 per cent to 41.1 million yuan (S$8.1 million) in the first half of 2006. The group said the sale of in-house drugs drove its profit-margin growth, and that a steady pipeline of new products and the acquisition of strategic targets will be its key growth driver.